These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21071929)

  • 1. Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis.
    Lewis G; Hall P; Eisa N; Deremer D; Dobbins R; El-Geneidy M; Jillella A; Ustun C
    Acta Haematol; 2010; 124(4):206-13. PubMed ID: 21071929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy: A Multicenter, Prospective, Observational Study in China.
    Wang L; Hu J; Sun Y; Huang H; Chen J; Li J; Ma J; Li J; Liang Y; Wang J; Li Y; Yu K; Hu J; Jin J; Wang C; Wu D; Xiao Y; Huang X
    Medicine (Baltimore); 2016 Jan; 95(4):e2560. PubMed ID: 26825897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis.
    Kaya Z; Gursel T; Kocak U; Aral YZ; Kalkanci A; Albayrak M
    Pediatr Blood Cancer; 2009 Apr; 52(4):470-5. PubMed ID: 19058205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
    Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
    Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis.
    Cornely OA; Böhme A; Reichert D; Reuter S; Maschmeyer G; Maertens J; Buchheidt D; Paluszewska M; Arenz D; Bethe U; Effelsberg J; Lövenich H; Sieniawski M; Haas A; Einsele H; Eimermacher H; Martino R; Silling G; Hahn M; Wacker S; Ullmann AJ; Karthaus M;
    J Antimicrob Chemother; 2008 Apr; 61(4):939-46. PubMed ID: 18272515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
    Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
    Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group.
    Kern W; Behre G; Rudolf T; Kerkhoff A; Grote-Metke A; Eimermacher H; Kubica U; Wörmann B; Büchner T; Hiddemann W
    Cancer; 1998 Jul; 83(2):291-301. PubMed ID: 9669812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
    Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
    N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study.
    Shen Y; Huang XJ; Wang JX; Jin J; Hu JD; Yu K; Wu DP; Wang SJ; Yu L; Chen XQ; Liu T; Liang YM; Chen FP; Li Y; Shen ZX
    Int J Clin Pharmacol Ther; 2013 Sep; 51(9):738-45. PubMed ID: 23924680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasive fungal infections in pediatric patients with hematologic malignancies receiving oral amphotericin B solution and early intravenous administration of fluconazole.
    Watanabe N; Matsumoto K; Kojima S; Kato K
    J Pediatr Hematol Oncol; 2011 May; 33(4):270-5. PubMed ID: 21464763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of fluconazole prophylaxis for prevention of invasive fungal infection in extremely low birth weight infants.
    Aziz M; Patel AL; Losavio J; Iyengar A; Berven M; Schloemer N; Jakubowicz A; Mathai T; McAuley JB
    Pediatr Infect Dis J; 2010 Apr; 29(4):352-6. PubMed ID: 19934791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Universal prophylaxis with fluconazole for the prevention of early invasive fungal infection in low-risk liver transplant recipients.
    San-Juan R; Aguado JM; Lumbreras C; Fortun J; Len O; Muñoz P; Montejo M; Moreno A; Cordero E; Blanes M; Ramos A; de la Torre-Cisneros J; Lopez-Medrano F; Carratala J; Moreno E;
    Transplantation; 2011 Aug; 92(3):346-50. PubMed ID: 21709604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
    Bassan R; Raimondi R; Lerede T; D'emilio A; Buelli M; Borleri G; Personeni A; Bellavita P; Rodeghiero F; Barbui T
    Haematologica; 1998 Jul; 83(7):627-35. PubMed ID: 9718868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.
    Glasmacher A; Cornely O; Ullmann AJ; Wedding U; Bodenstein H; Wandt H; Boewer C; Pasold R; Wolf HH; Hänel M; Dölken G; Junghanss C; Andreesen R; Bertz H;
    J Antimicrob Chemother; 2006 Feb; 57(2):317-25. PubMed ID: 16339606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group.
    Rotstein C; Bow EJ; Laverdiere M; Ioannou S; Carr D; Moghaddam N
    Clin Infect Dis; 1999 Feb; 28(2):331-40. PubMed ID: 10064252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.
    Maertens J; Theunissen K; Verhoef G; Verschakelen J; Lagrou K; Verbeken E; Wilmer A; Verhaegen J; Boogaerts M; Van Eldere J
    Clin Infect Dis; 2005 Nov; 41(9):1242-50. PubMed ID: 16206097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.
    Maertens J
    Eur J Haematol; 2007 Apr; 78(4):275-82. PubMed ID: 17241370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Invasive fungal infections in liver transplant recipients: analysis of 21 cases].
    Miguélez M; Lumbreras C; Herrero JA; Aguado JM; del Palacio A; Colina F; Gómez R; Lizasoain M; Moreno E; Rodríguez-Noriega A
    Med Clin (Barc); 1998 Mar; 110(11):406-10. PubMed ID: 9608495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.
    Oren I; Rowe JM; Sprecher H; Tamir A; Benyamini N; Akria L; Gorelik A; Dally N; Zuckerman T; Haddad N; Fineman R; Dann EJ
    Bone Marrow Transplant; 2006 Jul; 38(2):127-34. PubMed ID: 16751782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
    Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH
    Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.